The difference between conventional radiotherapy and hypfractionated intensity modulated radiotherapy on health-related quality of life in stage I-II breast cancer survivors: A 7-year follow-up of a randomized controlled trial

Vertaalde titel van de scriptie/masterproef: Het verschil tussen conventionele radiotherapie en hypofractionatie intensiteit-gemoduleerde radiotherapie op gezondheidsgerelateerde levenskwaliteit bij stadium I-II borstkanker overlevenden: een 7-jaar follow-up van een gerandomiseerde clinical trial

Scriptie/Masterproef: Master's Thesis

Samenvatting

Background
Primary treatment for breast cancer may include radiotherapy (RT) in patients who underwent surgery. In hypofractionated RT (HF-RT) treatment time is reduced, compared to conventional RT (CR). Tomotherapy is a combination of image-guided RT and intensity-modulated RT. By the decline in mortality and incline in survival the long-term health-related quality of life (HR-QOL) has become more important.
Aim
The aim of this study is to analyse the difference in HR-QOL between CR and HF-RT over a 7-year period. The hypothesis is that the HF-RT-group will not have inferior HR-QOL outcomes than the CR-group.
Methods
Patients were randomised to the CR-group or the HF-RT-group. CR-patients received irradiation of 50 Gy in 25 fractions over 5 weeks. HF-RT-patients received irradiation of 42 Gy in 15 fractions over 3 weeks, using Tomotherapy. HR-QOL was assessed with the EORTC QLQ-C30 and QLQ-BR23. Descriptive analyses were made using graphs. Independent sample t-tests were used to compare treatment arms.
Results
100 patients were included in this study, 53 patients in the CR group and 47 in the HF-RT group. The return rates were high during the first 5 years of follow-up (80%) and decreased significantly at 6- and 7-years follow-up (26% and 34%). Regarding the evolution over time in the QLQ-C30, role functioning in both groups, social functioning in the CR-group and cognitive functioning and global health status in the HF-RT-group increased moderately. Fatigue decreased moderately in the CR-group at 7-years follow-up. Insomnia improved in both groups. For the evolution in the QLQ-BR23 future perspective improved in both groups. Sexual functioning improved, and breast symptoms decreased in the HF-RT-group. Arm symptoms decreased in both groups. No differences were found between groups.
Conclusion
HF-IMRT can be used to treat BC patients, without affecting the HR-QOL in a negative way on a long-term base, compared to CR.
Datum prijs2018
Originele taalEnglish

Citeer dit

'